Lirilumab is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lirilumab’s likelihood of approval (LoA) and phase transition for Muscle Invasive Bladder Cancer (MIBC) took place on 28 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lirilumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lirilumab overview

Lirilumab (IPH-2102, BMS-986015) is under development for the treatment of hematologic tumors including refractory or relapsed multiple myeloma and muscle invasive bladder cancer. The drug candidate is administered intravenously. It targets killer cell immunoglobulin-like receptor 2DL 1, 2 and 3. The drug candidate is a new chemical entity.

It was also under development for castrate resistant prostate cancer, colorectal cancer, metastatic melanoma, advanced solid tumors including non-small cell lung cancer, gastrointestinal tract cancer,  head and neck cancer, squamous cell carcinoma, hepatocellular carcinoma, myelodysplastic syndrome, Hodgkin lymphoma, non-Hodgkin lymphoma and acute myeloid leukemia (AML).

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View Lirilumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Lirilumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.